Xeris Biopharma (XERS) Revenue & Revenue Breakdown
Xeris Biopharma Revenue Highlights
Latest Revenue (Y)
$163.91M
Latest Revenue (Q)
$52.86M
Main Segment (Y)
Product
Xeris Biopharma Revenue by Period
Xeris Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $163.91M | 48.68% |
| 2022-12-31 | $110.25M | - |
| 2021-12-31 | $110.25M | 122.32% |
| 2020-12-31 | $49.59M | 146.04% |
| 2019-12-31 | $20.16M | 717.65% |
| 2018-12-31 | $2.46M | 58.42% |
| 2017-12-31 | $1.56M | 44.74% |
| 2016-12-31 | $1.07M | - |
Xeris Biopharma generated $163.91M in revenue during NA 2024, up 48.68% compared to the previous quarter, and up 6649.66% compared to the same period a year ago.
Xeris Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $52.86M | 9.98% |
| 2024-06-30 | $48.06M | 18.28% |
| 2024-03-31 | $40.64M | -8.45% |
| 2023-12-31 | $44.39M | -8.13% |
| 2023-09-30 | $48.32M | 27.13% |
| 2023-06-30 | $38.01M | 14.50% |
| 2023-03-31 | $33.20M | -12.66% |
| 2022-12-31 | $38.01M | 27.87% |
| 2022-09-30 | $29.73M | 17.46% |
| 2022-06-30 | $25.31M | 14.65% |
| 2022-03-31 | $22.07M | 3.01% |
| 2021-12-31 | $21.43M | 94.19% |
| 2021-09-30 | $11.04M | 23.91% |
| 2021-06-30 | $8.91M | 10.62% |
| 2021-03-31 | $8.05M | 13.57% |
| 2020-12-31 | $7.09M | -24.97% |
| 2020-09-30 | $9.45M | 366.11% |
| 2020-06-30 | $2.03M | 13.37% |
| 2020-03-31 | $1.79M | -4.08% |
| 2019-12-31 | $1.86M | 477.09% |
| 2019-09-30 | $323.00K | 0.94% |
| 2019-06-30 | $320.00K | 29.03% |
| 2019-03-31 | $248.00K | -69.04% |
| 2018-12-31 | $801.00K | 37.63% |
| 2018-09-30 | $582.00K | -28.94% |
| 2018-06-30 | $819.00K | 211.41% |
| 2018-03-31 | $263.00K | -43.68% |
| 2017-12-31 | $467.00K | 174.71% |
| 2017-09-30 | $170.00K | -69.91% |
| 2017-06-30 | $565.00K | 59.60% |
| 2017-03-31 | $354.00K | - |
Xeris Biopharma generated $52.86M in revenue during Q1 2025, up 9.98% compared to the previous quarter, and up 139.08% compared to the same period a year ago.
Xeris Biopharma Revenue Breakdown
Xeris Biopharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| Keveyis | $49.53M | $56.77M | $49.31M |
| Product | $196.64M | $153.36M | $109.26M |
Latest
Xeris Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (79.88%), and Keveyis (20.12%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Keveyis | $24.25M | $12.19M | $13.09M | $40.91M | $15.87M | $14.09M | $12.76M | $13.80M | $13.37M | $12.81M |
| Product | $103.51M | $52.86M | $40.26M | $111.67M | $41.70M | $36.89M | $32.27M | $32.54M | $29.55M | $25.26M |
Latest
Xeris Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (81.02%), and Keveyis (18.98%).
Xeris Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| XERS | Xeris Biopharma | $163.91M | $52.86M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| IBRX | ImmunityBio | $14.74M | $1.05M |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| CDTX | Cidara Therapeutics | $1.27M | - |
| MCRB | Seres Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ELEV | Elevation Oncology | - | - |
| HOOK | HOOKIPA Pharma | - | $4.70M |
| MREO | Mereo BioPharma Group | - | - |